Pfizer creates chief operating officer role for Bourla

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. TSCO
9. BE
10. SLM

Go back to Pfizer creates chief operating officer role for Bourla

AstraZeneca (AZN) Granted FDA Aprproval for FASLODEX (fulvestrant) in Combination with Abemaciclib

November 15, 2017 7:01 AM EST

AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved a new indication for FASLODEX® (fulvestrant), expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) in women with disease progression after endocrine therapy.1

Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit, said: FASLODEX has long been an effective monotherapy option for women with hormone receptor positive breast cancer, which is the... More